Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ella Daly

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|September 26, 2006
Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationaleMadhukar H Trivedi, Cynthia A Claassen, Bruce D Grannemann, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Acta Psychiatrica Scandinavica|November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depressionIbrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Brain and Behavior|January 6, 2021
How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Jennifer Voelker, Kruti Joshi, Ella Daly, et al.
Psychiatry Research|August 21, 2020
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE StudyH Lynn Starr, Jill Abell, Allyson Larish, et al.
The International Journal of Neuropsychopharmacology|April 10, 2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 DataMichel Nijs, Ewa Wajs, Leah Aluisio, et al.
Brain and Behavior|July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder aloneDavid M Kern, Carla M Canuso, Ella Daly, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 26, 2016
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depressionJustine M Kent, Ella Daly, Iva Kezic, et al.
The Journal of Clinical Psychiatry|July 21, 2021
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM StudiesIbrahim Turkoz, Ella Daly, Jaskaran Singh, et al.
The International Journal of Neuropsychopharmacology|November 8, 2024
Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 StudiesRandall L Morrison, Jaskaran Singh, Ella Daly, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|September 26, 2006
Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationaleMadhukar H Trivedi, Cynthia A Claassen, Bruce D Grannemann, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Acta Psychiatrica Scandinavica|November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depressionIbrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Brain and Behavior|January 6, 2021
How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Jennifer Voelker, Kruti Joshi, Ella Daly, et al.
Psychiatry Research|August 21, 2020
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE StudyH Lynn Starr, Jill Abell, Allyson Larish, et al.
The International Journal of Neuropsychopharmacology|April 10, 2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 DataMichel Nijs, Ewa Wajs, Leah Aluisio, et al.
Brain and Behavior|July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder aloneDavid M Kern, Carla M Canuso, Ella Daly, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 26, 2016
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depressionJustine M Kent, Ella Daly, Iva Kezic, et al.
The Journal of Clinical Psychiatry|July 21, 2021
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM StudiesIbrahim Turkoz, Ella Daly, Jaskaran Singh, et al.
The International Journal of Neuropsychopharmacology|November 8, 2024
Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 StudiesRandall L Morrison, Jaskaran Singh, Ella Daly, et al.
Pageof 3